RGA(US:RGA)2026-02-06 16:02Financial Data and Key Metrics Changes - The company reported Q4 operating EPS of $7.75 per share, marking the second consecutive record quarter in earnings [6] - Adjusted operating return on equity (ROE) for the trailing 12 months was 15.7%, exceeding the intermediate-term target range of 13%-15% [6][18] - For the full year 2025, the company achieved record operating EPS and increased the value of in-force business margins by 18% [6][13] Business Line Data and Key Metrics Changes - In the U.S., favorable results were driven by management actions and variable investment income, with individual life mortality in line with expectations [7] - EMEA results showed strong volume growth and favorable experience, with full-year pre-tax earnings up 35% [11] - APAC region reported an 18% increase in pre-tax operating income, reflecting strong underlying growth and favorable underwriting experience [10] Market Data and Key Metrics Changes - Premium growth was 7.4% year-to-date on a constant currency basis, benefiting from strong growth across North America, EMEA, and APAC [19] - The U.S. healthcare business has approximately $400 million of annual premium, generating about $25 million of pre-tax run rate earnings in a typical year [43] Company Strategy and Development Direction - The company plans to exit the group healthcare lines of business after 2026, focusing on strategically aligned businesses [12][43] - The strategy includes optimizing the balance sheet, enhancing risk-adjusted investment returns, and maintaining a focus on capital stewardship [15][16] - The company aims for a balanced approach to capital deployment, targeting a total payout ratio of 20%-30% for buybacks and dividends [37][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet or exceed intermediate-term financial targets, citing strong momentum and a clear focus on strategy [16][33] - The company anticipates a more limited financial impact from in-force management actions in 2026 compared to recent years [24][91] - Management noted that higher interest rates are beneficial for overall earnings, given positive reinvestment cash flows [95] Other Important Information - The company deployed $2.5 billion of capital into in-force transactions for the full year, with $98 million in Q4 [19][20] - The effective tax rate for Q4 was 23.8%, with an expectation of 22%-23% for 2026 [20] - The company reported an estimated excess capital of $2.7 billion at the end of the quarter [30] Q&A Session Summary Question: Capital allocation and payout ratio - Management confirmed the target of a 20%-30% total payout ratio while maintaining flexibility for capital deployment [37] Question: Group health rate actions and business exit - Significant rate actions were taken, including a 40% average increase, and the decision to exit the group healthcare business was driven by strategic alignment [42][43] Question: Equitable block performance - The Equitable transaction is expected to generate $160 million-$170 million of earnings in 2026, with various factors contributing to economic upside [49] Question: Long-term care risk transfer deal performance - Management expressed satisfaction with the long-term care business performance, aligning with risk appetite and return expectations [62] Question: Investment portfolio exposure to software-related companies - The company has modest exposure to software lending, and AI impacts are actively monitored across the portfolio [67][68] Question: Regulatory changes in Europe and competition - Management noted no significant competitive threats arising from regulatory changes in Europe, focusing on opportunities with both asset and biometric risks [76][78] Question: Attractive regions or product lines for 2026 - The company highlighted a strong pipeline in Asia and the U.K. longevity market, with optimism about delivering attractive returns [81]